In the recently published literature, it has been consistently demonstrated that HER2-low BC is enriched in HR+ tumors and majority of HER2-low tumors are ER+ [16,19,25,26,27,28,29,30,31], indicating ER signaling contributes significantly to the HER2-low expression and related tumor biology. Here, ERBB2 is linked to breast cancer.